Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
  • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/10—Antimycotics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• the present invention relates to a pharmaceutical formulation comprising a pharmaceutically active agent; water; a polyethylene glycol or a poloxamer; and a polyethylene glycol mono- or di-ether.
• the pharmaceutically active agent is an anti-fungal or anti-mycotic agent.
• the pharmaceutically active agent is lipophilic and/or keratinophilic.
• the present invention also relates to the use of the formulation in treating diseases, disorders or pathological conditions of the nail or skin, such as onychomycosis, dermatomycosis and other mycoses.
• the present invention also relates to a method of administering a pharmaceutically active agent to a subject by applying the formulation comprising the pharmaceutically active agent to a nail or skin of the subject.
• the present invention further relates to a method of preparing the formulation.
• onychomycosis In particular fungal infections of the nails remain ineffectively treated. Fungal infections in, under and around fingernails and toenails are generally referred to as onychomycosis. Onychomycosis is most frequently caused by dermatophytes such as Trichophyton rubrum, Trichophyton mentagrophytes and Epidermophyton floccosum, but can also be caused by other types of fungi including moulds, yeasts and the like. Onychomycosis that is not caused by dermatophytes is normally caused by Candida species. Mixed infections can also occur. Onychomycosis causes thickening, roughness, splitting and discolouration of the nail and can even result in its loss or destruction. In addition, it can be the cause of pain, inadequate blood supply, problems with walking, and other undesirable phenomena.
• dermatophytes such as Trichophyton rubrum, Trichophyton mentagrophytes and Epidermophyton floccosum
• Candida species Mixed infections can also occur.
• onychomycosis was treated inter alia by removing the affected part of the nail or the whole nail.
• this type of treatment can lead to permanent damage to the nail.
• the newly growing nail can grow in a misshapen form.
• onychomycosis can also be treated by the use of various anti-mycotic agents.
• the anti-mycotic agents can be administered orally, for example.
• stress is put on the body as a whole and only a small amount of the anti-mycotically active substance reaches the nail via the nail matrix.
• Oral treatment has the further disadvantage that such treatment requires a treatment time of at least 12 weeks for toenails and about 6 to 8 weeks for fingernails. Such long treatment times make the treatment expensive and reduce patient compliance.
• oral treatment increases the risk of side-effects, such as, for example, irritation of the gastro-intestinal tract, nausea, undesirable interactions with other medicaments, active ingredient induced skin rashes etc.
• the oral treatment of onychomycosis is further rendered difficult by variable rates of absorption and metabolism.
• Another method of treating onychomycosis comprises the topical application of a pharmaceutical formulation containing an anti-mycotic active ingredient.
• a pharmaceutical formulation containing an anti-mycotic active ingredient For example, it is known to treat onychomycosis with nail lacquer formulations that contain an anti-mycotic active ingredient.
• nail lacquer formulations that contain an anti-mycotic active ingredient.
• anti-fungal nail lacquers lack the necessary penetrating power to reach the fungal infection, because the nail is a difficult barrier for the anti-fungal compounds to penetrate.
• a first aspect of the present invention provides a formulation comprising:
• a polyethylene glycol (PEG) has the general formula HO-(CH 2 CH 2 O) n -H.
• the polyethylene glycol has a mean molecular weight of at least 400, preferably at least 500, preferably at least 700, preferably at least 1000, preferably at least 1500, preferably at least 4500, preferably at least 5000, preferably at least 6000, and more preferably at least 8000.
• the mean molecular weight of the polyethylene glycol is no more than 100000, preferably no more than 30000, and more preferably no more than 20000.
• the mean molecular weight of the polyethylene glycol is in the range of 200-100000, preferably in the range of 300-30000.
• the polyethylene glycol is PEG 8000 - 20000, i.e. a polyethylene glycol having a mean molecular weight between 8000 and 20000.
• the mean molecular weight of the polyethylene glycol is in the range of 200-600, preferably in the range of 300- 500, and more preferably the mean molecular weight of the polyethylene glycol is about 400.
• the formulation comprises the polyethylene - A -
• glycol in an amount of 5-50%, preferably in an amount of 10-40%, preferably in an amount of 15-35%.
• a poloxamer is a polyethylene glycol-polypropylene glycol block copolymer with the general formula HO-(CH 2 CH 2 O) a -(CH(CH 3 )CH 2 O) b -(CH 2 CH 2 O) c -H.
• a 4-200.
• b 15-350.
• c 4-200.
• the polyoxyethylene content of the poloxamer is 10-80% of the total polymer weight.
• the poloxamer has a mean molecular weight of at least 1000, preferably at least 2000, preferably at least 4500, preferably at least 5000, preferably at least 6000, and more preferably at least 8000.
• the mean molecular weight of the poloxamer is no more than 100000, preferably no more than 30000, and more preferably no more than 15000. Any of these preferred lower molecular weight limits can be combined with any of these preferred upper molecular weight limits to give preferred molecular weight ranges.
• the mean molecular weight of the poloxamer is in the range of 1000-16000, preferably in the range of 2000-15000.
• the formulation comprises the poloxamer in an amount of at least 1%, preferably at least 2%, preferably at least 5%.
• the formulation comprises the poloxamer in an amount of 5- 50%, preferably in an amount of 10-40%, preferably in an amount of 15-35%.
• the formulation of the present invention may comprise a polyethylene glycol or a poloxamer.
• the formulation comprises a polyethylene glycol.
• the formulation does not comprise a poloxamer.
• a polyethylene glycol mono- or di-ether has the general formula RO-(CH 2 CH 2 O) 1n -R.
• each R is independently selected from hydrogen or an optionally substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl or alkynylaryl group; more preferably each R is independently selected from hydrogen or an optionally substituted alkyl, aryl, arylalkyl or alkylaryl group; more preferably each R is independently selected from hydrogen or an optionally substituted alkyl group; more preferably each R is independently selected from hydrogen or a methyl or ethyl group; all provided that at least one R is not hydrogen.
• one R is hydrogen.
• R is not substituted.
• R comprises no heteroatoms in its carbon skeleton.
• R contains from 1 to 20 carbon atoms, preferably from 1 to 15 carbon atoms, preferably from 1 to 10 carbon atoms, preferably from 1 to 5 carbon atoms, more preferably from 1 to 4 carbon atoms.
• the polyethylene glycol mono- or di-ether contains a single -(CH 2 CH 2 O) 1n - group, i.e. no R comprises a -(CH 2 CH 2 O) 1n - group.
• the mean molecular weight of the polyethylene glycol mono- or di-ether is in the range of 120-10000, preferably in the range of 200-8000, preferably in the range of 300-5000.
• the formulation comprises the polyethylene glycol mono- or di-ether in an amount of 0.1-30%, preferably in an amount of 2-15%, preferably in an amount of 3-10%, more preferably in an amount of about 5%.
• the formulation comprises the polyethylene glycol mono- or di-ether in an amount of 4-30%, preferably in an amount of 4-20%, more preferably in an amount of about 5%.
• the formulation comprises a polyethylene glycol mono-ether.
• the formulation comprises a polyethylene glycol di-ether, preferably wherein each R independently contains from 1 to 20 carbon atoms, preferably from 1 to 15 carbon atoms, preferably from 1 to 10 carbon atoms, preferably from 1 to 5 carbon atoms, more preferably from 1 to 4 carbon atoms.
• the polyethylene glycol mono- or di-ether is a polyethylene glycol mono- or di-methyl or ethyl ether, more preferably the polyethylene glycol mono- or di-ether is polyethylene glycol monomethyl ether (MPEG).
• MPEG polyethylene glycol monomethyl ether
• the polyethylene glycol monomethyl ether is MPEG 350 - 10000, i.e. a polyethylene glycol monomethyl ether having a mean molecular weight between 350 and 10000. More preferably, the polyethylene glycol monomethyl ether is MPEG 350 - 5000, i.e. a polyethylene glycol monomethyl ether having a mean molecular weight between 350 and 5000.
• the polyethylene glycol monomethyl ether is MPEG 2000, i.e. a polyethylene glycol monomethyl ether having a mean molecular weight of about 2000.
• the formulation comprises polyethylene glycol monomethyl ether in an amount of 2- 15%, preferably in an amount of 3-10%.
• the polyethylene glycol (PEG) or poloxamer on the one hand and the polyethylene glycol mono- or di-ether on the other hand are used in a ratio of at least 1 :1, preferably at least 2:1, more preferably at least 3:1.
• the polyethylene glycol (PEG) or poloxamer on the one hand and the polyethylene glycol mono- or di-ether on the other hand are used in a ratio of no more than 10:1, preferably no more than 8:1, more preferably no more than 6:1. Any of these preferred lower ratios can be combined with any of these preferred upper ratios to give preferred ratio ranges.
• the polyethylene glycol (PEG) or poloxamer on the one hand and the polyethylene glycol mono- or di-ether on the other hand are used in a ratio of from 10:1 to 1 :1, preferably in a ratio of about 4:1.
• an 'alkyl' group is defined as a monovalent saturated hydrocarbon, which may be straight-chained or branched, or be or include cyclic groups.
• An alkyl group may optionally include one or more heteroatoms N, O or S in its carbon skeleton.
• alkyl groups are methyl, ethyl, »-propyl, /-propyl, »-butyl, /-butyl, /-butyl and »-pentyl groups.
• an alkyl group is straight-chained or branched and does not include any heteroatoms in its carbon skeleton.
• an alkyl group is a C 1 -C 12 alkyl group, which is defined as an alkyl group containing from 1 to 12 carbon atoms. More preferably an alkyl group is a C 1 -C 6 alkyl group, which is defined as an alkyl group containing from 1 to 6 carbon atoms.
• An 'alkylene' group is similarly defined as a divalent alkyl group.
• An 'alkenyl' group is defined as a monovalent hydrocarbon, which comprises at least one carbon-carbon double bond, which may be straight-chained or branched, or be or include cyclic groups.
• An alkenyl group may optionally include one or more heteroatoms N, O or S in its carbon skeleton.
• alkenyl groups are vinyl, allyl, but-1-enyl and but-2-enyl groups.
• an alkenyl group is straight-chained or branched and does not include any heteroatoms in its carbon skeleton.
• an alkenyl group is a C 2 -C 12 alkenyl group, which is defined as an alkenyl group containing from 2 to 12 carbon atoms.
• an alkenyl group is a C 2 -C 6 alkenyl group, which is defined as an alkenyl group containing from 2 to 6 carbon atoms.
• An 'alkenylene' group is similarly defined as a divalent alkenyl group.
• An 'alkynyl' group is defined as a monovalent hydrocarbon, which comprises at least one carbon-carbon triple bond, which may be straight-chained or branched, or be or include cyclic groups.
• An alkynyl group may optionally include one or more heteroatoms N, O or S in its carbon skeleton. Examples of alkynyl groups are ethynyl, propargyl, but-1-ynyl and but-2-ynyl groups.
• an alkynyl group is straight-chained or branched and does not include any heteroatoms in its carbon skeleton.
• an alkynyl group is a C 2 -C 12 alkynyl group, which is defined as an alkynyl group containing from 2 to 12 carbon atoms. More preferably an alkynyl group is a C 2 -C 6 alkynyl group, which is defined as an alkynyl group containing from 2 to 6 carbon atoms.
• An 'alkynylene' group is similarly defined as a divalent alkynyl group.
• An 'aryl' group is defined as a monovalent aromatic hydrocarbon.
• An aryl group may optionally include one or more heteroatoms N, O or S in its carbon skeleton.
• Examples of aryl groups are phenyl, naphthyl, anthracenyl and phenanthrenyl groups.
• Preferably an aryl group does not include any heteroatoms in its carbon skeleton.
• Preferably an aryl group is a C 4 -C 14 aryl group, which is defined as an aryl group containing from 4 to 14 carbon atoms. More preferably an aryl group is a C 6 - C 10 aryl group, which is defined as an aryl group containing from 6 to 10 carbon atoms.
• An 'arylene' group is similarly defined as a divalent aryl group.
• arylalkyl arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl or alkynylaryl
• the last mentioned group contains the atom by which the moiety is attached to the rest of the molecule.
• a typical example of an arylalkyl group is benzyl.
• an optionally substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl or alkynylaryl group may be substituted with one or more of -F, -Cl, -Br, -I, -CF 3 , -CCl 3 , -CBr 3 , -CI 3 , -OH, -SH, -NH 2 , -CN, -NO 2 , -COOH, -R ⁇ -O-R ⁇ , -R ⁇ -S-R ⁇ , -R ⁇ -SO-R ⁇ , -R ⁇ -SO 2 -R ⁇ , -R ⁇ -SO 2 -R ⁇ , -R ⁇ -SO 2 -OR ⁇ , -RO-SO 2 -R ⁇ , -
• -R ⁇ - is independently a chemical bond, a C 1 -C 10 alkylene, C 1 -C 10 alkenylene or C 1 -C 10 alkynylene group.
• -R ⁇ is independently hydrogen, unsubstituted C 1 -C 6 alkyl or unsubstituted C 6 -C 10 aryl.
• Optional substituent(s) are taken into account when calculating the total number of carbon atoms in the parent group substituted with the optional substituent(s).
• an optionally substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl or alkynylaryl group is not substituted with a bridging substituent.
• an optionally substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl or alkynylaryl group is not substituted with a ⁇ -bonded substituent.
• a substituted group comprises 1, 2 or 3 substituents, more preferably 1 or 2 substituents, and even more preferably 1 substituent.
• the formulation comprises:
• the formulation comprises:
• the formulation comprises: (a) 0.1-30% pharmaceutically active agent; (b) 5-50% water;
• the pharmaceutically active agent is an anti-fungal or anti-mycotic agent.
• the terms 'anti-fungal' and 'anti-mycotic' are used interchangeable herein.
• the pharmaceutically active agent is lipophilic and/or keratinophilic.
• the anti-fungal or anti-mycotic agent is an azole, imidazole, triazole, thiazole, thiadiazole, guanidine, pyrimidine, imine, morpholine, 2-pyridone, 2-pyrimidone, allylamine, benzylamine, polyene, echinocandin, benzofuran, benzoxaborole, pyridine, or thio carbamate.
• the anti-fungal or anti- mycotic agent is an imidazole, then it is preferably bifonazole, clotrimazole, econazole, fenticonazole, isoconazole, ketoconazole, miconazole, oxiconazole, tioconazole, sertaconazole, sulconazole, or a pharmaceutically acceptable salt thereof.
• the anti-fungal or anti-mycotic agent is a triazole, then it is preferably fluconazole, itraconazole, posaconazole, ravuconazole, terconazole, voriconazole, or a pharmaceutically acceptable salt thereof.
• the anti-fungal or anti-mycotic agent is a thiazole, then it is preferably a 2-amino-thiazole, preferably abafungin or a pharmaceutically acceptable salt thereof. If the anti-fungal or anti-mycotic agent is a guanidine, then it is preferably an arylguanidine, preferably abafungin or a pharmaceutically acceptable salt thereof. If the anti-fungal or anti-mycotic agent is a pyrimidine, then it is preferably a 2-pyrimidinimine, preferably abafungin or a pharmaceutically acceptable salt thereof.
• the anti-fungal or anti-mycotic agent is an imine, then it is preferably a 2-pyrimidinimine, preferably abafungin or a pharmaceutically acceptable salt thereof. If the anti-fungal or anti-mycotic agent is a morpholine, then it is preferably amorolfine or a pharmaceutically acceptable salt thereof. If the anti- fungal or anti-mycotic agent is a 2-pyridone, then it is preferably ciclopirox or a pharmaceutically acceptable salt thereof. If the anti-fungal or anti- mycotic agent is a 2-pyrimidone, then it is preferably flucytosine or a pharmaceutically acceptable salt thereof.
• the anti-fungal or anti-mycotic agent is an allylamine, then it is preferably terbinafine, naftifine, or a pharmaceutically acceptable salt thereof. If the anti-fungal or anti-mycotic agent is a benzylamine, then it is preferably butenafine or a pharmaceutically acceptable salt thereof. If the anti-fungal or anti-mycotic agent is a polyene, then it is preferably amphotericin B, nystatin, pimaricin (also called natamycin), or a pharmaceutically acceptable salt thereof.
• the anti-fungal or anti-mycotic agent is an echinocandin, then it is preferably caspofungin, micafungin, anidulafungin, or a pharmaceutically acceptable salt thereof.
• the anti-fungal or anti-mycotic agent is abafungin or a pharmaceutically acceptable salt thereof, preferably abafungin.
• a compound is said to be an azole, imidazole, triazole, thiazole, 2-amino-thiazole, thiadiazole, guanidine, arylguanidine, pyrimidine, imine, 2-pyrimidinimine, morpholine, 2-pyridone, 2-pyrimidone, allylamine, benzylamine, polyene, echinocandin, benzofuran, benzoxaborole, pyridine, thiocarbamate etc, then this means that the compound comprises an azole, imidazole, triazole, thiazole, 2-amino-thiazole, thiadiazole, guanidine, arylguanidine, pyrimidine, imine, 2-pyrimidinimine, morpholine, 2-pyridone, 2-pyrimidone, allylamine, benzylamine, polyene, echinocandin, benzofuran, benzoxaborole, pyridine,
• Azoles are generally considered to be five-membered aromatic heterocycles comprising one nitrogen atom and at least one further heteroatom, such as a nitrogen, oxygen or sulphur atom. Therefore imidazoles (five-membered aromatic heterocycles comprising two nitrogen atoms), triazoles (five-membered aromatic heterocycles comprising three nitrogen atoms), thiazoles (five-membered aromatic heterocycles comprising one nitrogen atom and one sulphur atom), and thiadiazoles (five-membered aromatic heterocycles comprising two nitrogen atoms and one sulphur atom) are generally considered to be azoles.
• azole anti-fungal agents generally only imidazole and triazole anti-fungal agents are meant, not thiazole or thiadiazole anti-fungal agents. Without wishing to be bound by theory, this is because currently the anti-fungal activity of imidazole and triazole anti-fungal agents is believed to be due to the inhibition of the ergosterol biosynthesis by inhibiting 14 ⁇ -demethylase. Thiazole anti-fungal agents, on the other hand, are currently not believed to inhibit 14 ⁇ - demethylase and their anti-fungal activity is currently believed to be at least partially due to the inhibition of the ergosterol biosynthesis by inhibiting 24- sterolmethyltransferase.
• the term 'azole' encompasses all five-membered aromatic heterocycles comprising one nitrogen atom and at least one further heteroatom, and therefore includes imidazoles, triazoles, thiazoles, and thiadiazoles. In a preferred embodiment, the term 'azole' only encompasses imidazoles and triazoles.
• the anti-fungal or anti-mycotic agent is not a triazole. In another embodiment, the anti-fungal or anti-mycotic agent is not an imidazole. In another embodiment, the anti-fungal or anti-mycotic agent is a thiazole or a thiadiazole.
• the anti-fungal or anti-mycotic agent is a compound of the general formula (I):
• R 1 is hydrogen or alkyl
• R 2 is a group of the formula:
• R , R , R and R are independently hydrogen, halogen, nitro, alkyl, alkoxy, alkoxy-carbonyl, dialkylamino, alkylthio, alkylsulphinyl, alkylsulphonyl, haloalkyl, haloalkoxy, haloalkylthio, haloalkylsulphinyl, or haloalkylsulphonyl;
• X is oxygen, sulphur, sulphinyl, or sulphonyl;
• Ar is an optionally substituted aryl group; or a pharmaceutically acceptable salt thereof.
• the compounds of formula (I) are in equilibrium with their tautomers of formulae (Ia) and (Ib):
• R 1 is hydrogen or C 1 3 alkyl, preferably hydrogen.
• R 3 , R 4 , R 5 and R are independently hydrogen or C 1 3 alkyl, preferably hydrogen.
• X is oxygen.
• Ar is a phenyl group optionally substituted with one, two or three C 1 3 alkyl or C 1 3 alkoxy groups.
• R 2 is:
• the compounds of formula (I) can be classified as being 2-amino-thiazoles, or arylguanidines, or 2-pyrimidinimines.
• a preferred compound of the general formula (I) is abafungin of the formula (II):
• the anti-fungal or anti-mycotic agent is abafungin, ciclopirox olamine, terbinafine hydrochloride, or amorolfine.
• the anti-fungal or anti-mycotic agent is abafungin or a pharmaceutically acceptable salt thereof, preferably abafungin.
• the formulation preferably further comprises an acid such as formic acid for pH adjustment.
• the formulation has a pH in the range of about 5-8, preferably about 5-7, preferably about 5-6, preferably about 5.5, which simulates the conditions of human skin and nails.
• the formulation has a pH in the range of about 1 -7, preferably about 2-6, preferably about 3-6, preferably about 3-5, more preferably about 4-5.
• the formulation comprises the pharmaceutically active agent in an amount of 0.1-30%, preferably in an amount of 0.5-20%, preferably in an amount of 1-15%.
• the formulation comprises the pharmaceutically active agent in an amount of at least 2.5%, preferably at least 4%, preferably at least 5%, more preferably in an amount of about 10%.
• the pharmaceutically active agent is substantially dissolved in the formulation, i.e. at least 75% of the pharmaceutically active agent present in the formulation is in solution in the formulation.
• at least 90%, preferably at least 95%, preferably at least 98%, preferably at least 99%, more preferably at least 99.9% of the pharmaceutically active agent present in the formulation is in solution in the formulation.
• the formulation comprises water in an amount of 5- 50%, preferably in an amount of 10-50%, preferably in an amount of 17-25% or 20- 40%. More preferably the formulation comprises water in an amount of about 20%.
• the formulation further comprises an alcohol, such as 2-propanol, ethanol, benzyl alcohol, or 2-phenoxyethanol.
• the formulation may comprise up to 70% alcohol. If the formulation comprises an alcohol, it is preferably present in an amount of 10-70%, preferably in an amount of 20-60%, preferably in an amount of 30-50%.
• the formulation further comprises an acid or a base for pH adjustment.
• Suitable acids include organic fatty acids which may be saturated or unsaturated (such as citric acid, myristic acid and formic acid) and inorganic acids (such as hydrochloric acid and sulphuric acid).
• a preferred acid is formic acid.
• Suitable bases include sodium hydroxide.
• the formulation may comprise up to 5% acid or base.
• the formulation has a pH in the range of about 5-8, preferably about 5-7, preferably about 5-6, preferably about 5.5, which simulates the conditions of human skin and nails.
• the formulation has a pH in the range of about 1-7, preferably about 2-6, preferably about 3-6, preferably about 3-5, more preferably about 4-5.
• the formulation further comprises a penetration enhancer and/or a plasticizer.
• Preferred penetration enhancers and/or plasticizers include, but are not limited to isopropyl myristate, transcutol, propylene glycol, isopropyl palmitate, terpenoides, decyl oleate, oleic acid, sulphoxides, keratinolytics (such as urea), azones, terpenes, essential oils, surfactants (such as Tween 20, Tween 80, Span, Labrasol, Isoceteth-20), alcohols, polyols, fatty acids, glycols, and pyrrolidones.
• the formulation may comprise up to 10% penetration enhancer preferably up to 6%.
• the formulation may comprise up to 6% plasticizer, preferably up to 5%.
• the formulation comprises isopropyl myristate.
• the formulation may comprise up to 1% isopropyl myristate. If the formulation comprises isopropyl myristate, it is preferably present in an amount of 0.1-1%, preferably 0.5-1%.
• the formulation comprises a penetration enhancer such as transcutol.
• the formulation may comprise up to 4% transcutol. If the formulation comprises transcutol, it is preferably present in an amount of 0.5-4%, preferably in an amount of 1-4%, preferably in an amount of 2-4%.
• the formulation comprises propylene glycol.
• the formulation may comprise up to 5% propylene glycol. If the formulation comprises propylene glycol, it is preferably present in an amount of 0.5-5%, preferably in an amount of 0.5-4%, preferably in an amount of 0.5-3%.
• the formulation has a viscosity of at least 1100 mPas, preferably at least 1200 mPas, preferably at least 1300 mPas, preferably at least 1500 mPas, preferably at least 2000 mPas, preferably at least 5000 mPas, preferably at least 10000 mPas.
• the formulation has a viscosity of between 2 and 1000 mPas, preferably between 5 and 900 mPas, preferably between 10 and 750 mPas, preferably between 30 and 500 mPas.
• the formulation has a viscosity of between 100 and 500 mPas, preferably between 200 and 300 mPas, more preferably about 250 mPas.
• a viscosity of between 100 and 500 mPas, preferably between 200 and 300 mPas, more preferably about 250 mPas.
• such a formulation is suitable for application to the nail, preferably as a gel.
• the formulation has a viscosity of between 30 and 100 mPas, preferably between 40 and 80 mPas, more preferably about 60 mPas.
• a formulation is suitable for application to the skin, preferably as a spray.
• the formulation is not a solid.
• the formulation is a spray, cream, ointment, gel or paste. More preferably the formulation is a hydrophilic water-based gel.
• the formulation of the present invention can be used for the treatment of a disease, disorder or pathological condition of the nail or skin.
• the formulation of the present invention can be used for the treatment of onychomycoses, dermatomycoses, oral, vaginal or anal mycoses, skin diseases such as acne, topical bacterial infections such as Staphylococcus aureus, or topical viral infections such as herpes.
• the formulation of the present invention can also be used to aid wound healing.
• the formulation of the present invention is suitable for topical application, preferably to the nail or skin.
• the formulation of the present invention can be used for the treatment of a disease, disorder or pathological condition of the hooves, horn, claws or skin of a subject, preferably a non-human mammal such as a cow, pig, sheep, dog or cat.
• a disease, disorder or pathological condition is a fungal infection.
• a second aspect of the present invention provides a method of administering a pharmaceutically active agent to a subject, comprising applying a formulation according to the first aspect of the present invention to a nail of the subject.
• the pharmaceutically active agent is lipophilic and/or keratinophilic.
• Lipophilic and/or keratinophilic pharmaceutically active agents are often capable of penetrating skin. Hydrophilic pharmaceutically active agents are often capable of penetrating nails.
• the method of the second aspect of the present invention uses a hydrophilic formulation to make it possible for lipophilic and/or keratinophilic pharmaceutically active agents to penetrate nails.
• the subject is a human or non-human mammal, preferably a human.
• the pharmaceutically active agent penetrates into the subject's nail and nail matrix by penetrating through the nail and through the skin surrounding the nail.
• a third aspect of the present invention provides a method of treating onychomycosis, the method comprising applying a formulation according to the first aspect of the present invention to the nail of a subject suffering from onychomycosis.
• the third aspect of the present invention also provides a method of treating dermatomycosis, the method comprising applying a formulation according to the first aspect of the present invention to the skin of a subject suffering from dermatomycosis.
• the third aspect of the present invention further provides a method of treating an oral, vaginal or anal mycosis, the method comprising applying a formulation according to the first aspect of the present invention to the skin or mucosa of a subject suffering from the oral, vaginal or anal mycosis.
• the third aspect of the present invention further provides a method of treating a skin disease (such as acne), the method comprising applying a formulation according to the first aspect of the present invention to the skin of a subject suffering from the skin disease.
• a skin disease such as acne
• the third aspect of the present invention further provides a method of treating a topical bacterial infection (such as Staphylococcus aureus) or a topical viral infection (such as herpes), the method comprising applying a formulation according to the first aspect of the present invention to the skin or mucosa of a subject suffering from the topical infection.
• a topical bacterial infection such as Staphylococcus aureus
• a topical viral infection such as herpes
• the third aspect of the present invention further provides a method of aiding wound healing, the method comprising applying a formulation according to the first aspect of the present invention to the wound of a subject.
• the subject may be a human or non-human mammal.
• the subject is a human.
• a fourth aspect of the present invention provides a method of preparing a formulation according to the first aspect of the present invention, the method comprising the steps of:
• the pharmaceutically active agent can be protonated and an acid is used in step (a), which protonates the pharmaceutically active agent.
• a preferred pharmaceutically active agent, which can be protonated, is abafungin or a pharmaceutically acceptable salt thereof.
• the pharmaceutically active agent can be deprotonated and a base is used in step (a), which deprotonates the pharmaceutically active agent.
• any embodiment of a given aspect of the present invention may occur in combination with any other embodiment of the same aspect of the present invention.
• any preferred or optional embodiment of any aspect of the present invention should also be considered as a preferred or optional embodiment of any other aspect of the present invention.
• Figure 1 shows three horse hoof horn membranes (labelled 1, 2 and 3) 24 hours after the application of three formulations comprising abafungin.
• Figure 2 is a graph showing the amount of abafungin which has penetrated into horse hoof horn membranes 24 hours after the application of three formulations comprising abafungin.
• Figure 3 shows the toenail of a volunteer suffering from onychomycosis after topical application of a formulation of the present invention comprising abafungin.
• Figure 4 shows the toenails of another volunteer suffering from onychomycosis before treatment and after oral itraconazole administration and concurrent topical application of a formulation of the present invention comprising abafungin.
• '(I)' refers to the oral itraconazole administration
• 'Abagel 10%' refers to the topical application of the abafungin formulation.
• Figure 5 is a graph showing the amount of abafungin, ciclopirox or ciclopirox olamine which has penetrated into horse hoof horn membranes 24 hours after the application of five formulations comprising abafungin, ciclopirox or ciclopirox olamine.
• Figure 6 is a graph showing the amount of abafungin or hydrocortisone which has penetrated into porcine ear skin 24 hours after the application of four formulations comprising abafungin or hydrocortisone.
• Figure 7 is a graph showing the percentage deviation of TEWL (transepidermal water loss) measurements one hour after treatment with Batrafen ® , Loceryl ® or a formulation according to the present invention to the measurements before the treatment.
• TEWL transepidermal water loss
• Figure 8 shows a schematic diagram of a fungal inhibition zone.
• Figure 9 are photographs of Sabouraud plates inoculated with T. rubrum 34 and treated with bovine hoof horn membrane treated with four formulations comprising abafungin.
• a preferred formulation of the present invention is a water-based, hydrophilic, non- irritating gel formulation suitable for the treatment of onychomycosis, dermatomycosis and other mycoses (see examples 5 and 10).
• the formulation comprises a polyethylene glycol mono- or di-ether (preferably polyethylene glycol monomethyl ether (MPEG)) and a polyethylene glycol or a poloxamer (preferably polyethylene glycol (PEG)) as adhesives and film formers, which ensure that the formulation is capable of releasing pharmaceutically active agents slowly.
• Polyethylene glycols and poloxamers are known permeation enhancers and known for the sustained release of pharmaceutically active agents.
• Polyethylene glycol ethers, in particular MPEG are solubilisers and film builders. Without wishing to be bound by theory, it is thought that together they act as adhesives and film formers and ensure that the formulation of the present invention forms a breathable film incorporating a pharmaceutically active agent.
• the water naturally present in the nail or skin dissolves the pharmaceutically active agent out of the PEG or poloxamer / PEG-ether depot, which releases the pharmaceutically active agent slowly.
• the presence of the polyethylene glycol ether is thought to lead to higher interactions of all substances concerned, for example, the ether group is thought to lead to greater adhesion of the formulation to the organic nail or skin material.
• the ether group is also thought to be responsible for the observed high solubility of lipophilic and/or keratinophilic pharmaceutically active agents in the formulation.
• Known water-based formulations use swelling gel builders (e.g. hydroxymethyl cellulose) and/or water-soluble acrylic acid copolymers. These gel builders can be used in a concentration of only up to 1.5% in water, since otherwise the viscosity of the formulation becomes too high. However, such small amounts of gel builders are not enough to provide an effective depot for a pharmaceutically active agent.
• swelling gel builders e.g. hydroxymethyl cellulose
• acrylic acid copolymers e.g. hydroxymethyl cellulose
• These gel builders can be used in a concentration of only up to 1.5% in water, since otherwise the viscosity of the formulation becomes too high.
• such small amounts of gel builders are not enough to provide an effective depot for a pharmaceutically active agent.
• the hydrophilic gel formulations according to the present invention act as a depot for the pharmaceutically active agent.
• the water naturally present in the nail or skin dissolves the pharmaceutically active agent out of the PEG or poloxamer / PEG-ether depot, which releases the pharmaceutically active agent slowly, providing for a modified release such as delayed, extended, sustained or controlled release.
• compositions suitable for use in the formulation of the present invention include lipophilic and/or keratinophilic substances, e.g. anti-mycotics, which can be applied to the nail, skin and mucosa for the treatment of onychomycosis, dermatomycosis and other mycoses, such as oral, vaginal and rectal mycoses.
• lipophilic and/or keratinophilic substances e.g. anti-mycotics
• Suitable anti-mycotics include, but are not limited to azoles (such as imidazoles and triazoles), imidazoles (such as bifonazole, clotrimazole, econazole, fenticonazole, isoconazole, ketoconazole, miconazole, oxiconazole, tioconazole, sertaconazole, and sulconazole), triazoles (such as fluconazole, itraconazole, posaconazole, ravuconazole, terconazole, and voriconazole), thiazoles (such as 2- amino-thiazoles such as abafungin), thiadiazoles, guanidines (such as arylguanidines such as abafungin), pyrimidines (such as pyrimidinimines such as abafungin), imines (such as pyrimidinimines such as abafungin), morpholines (such as amorolfine), 2-
• the formulation comprises abafungin, ciclopirox olamine, terbinafine hydrochloride, or amorolfine; more preferably abafungin.
• a formulation comprising abafungin also preferably comprises an acid for adjusting the pH of the formulation, such that the abafungin in the formulation is protonated into the active molecule, the guanidinium ion.
• Lipophilic and/or keratinophilic pharmaceutically active agents, such as abafungin, ciclopirox olamine and terbinafine hydrochloride are surprisingly stable and soluble in the formulation of the present invention.
• abafungin is lipophilic and poorly soluble in many excipients (see example 1).
• a pharmaceutically active agent such as abafungin in a pharmaceutical formulation in an amount sufficient for an acceptable permeation rate (see examples 2, 3, 4, 6 and 7).
• the PEG or poloxamer / PEG-ether mixture of the formulation of the present invention makes it possible for a lipophilic and/or keratinophilic pharmaceutically active agent such as abafungin to be solubilised adequately and the PEG or poloxamer / PEG-ether mixture is thought to prevent the lipophilic and/or keratinophilic pharmaceutically active agent from crystallising out of the formulation.
• a concentration of up to 30% abafungin can be achieved in the formulation of the present invention (see example 8).
• compositions of the present invention also showed surprisingly much higher permeation rates into and across the nail and into the skin from the formulation of the present invention compared to conventional lacquer formulations and compared to hydrophilic nail gels without a polyethylene glycol ether (see examples 2, 3, 4, 6 and 7).
• the formulations according to the present invention are hydrophilic water-based gels, which allow water to pass into and out of the nail after application of the formulations to the nail. This is in contrast to conventional lacquers, which reduce the transungual diffusion of water significantly (de Berker & Baran, Int. J. Cosmetic Science, 2007, vol. 29, pages 241-275; Spruit, Am. Cosmet. Perfum., 1972, vol. 87, pages 57-58). This was also confirmed by example 9 below.
• Conventional anti-mycotic nail lacquers such as Penlac (also called Batrafen ) (ciclopirox) from Aventis and Loceryl (amorolfine) from Galderma, use alcohols as solvents and water insoluble polymers. Therefore the lacquer films formed from such conventional lacquers are water insoluble and the water which is naturally present in nails cannot dissolve the anti-mycotic agents out of the water insoluble polymer matrices. This results in a slow penetration rate of the anti-mycotic agents from the conventional lacquers into the nail.
• the formulations of the present invention on the other hand are hydrophilic and the pharmaceutically active agents move easily from the hydrophilic formulations into the nail water.
• the formulation of the present invention can deliver an anti-fungal or anti-mycotic agent to the nail plate (the stratum corneum unguis) and to the nail bed (the modified area of the epidermis beneath the nail, over which the nail plate slides as it grows) through the nail plate and around the nail periphery.
• the anti-fungal or anti-mycotic agent is also concurrently delivered to the nail matrix, the cuticle and the hyponychium (the thickened epidermis underneath the free distal end of a nail).
• the hydrophilic nature of the formulation of the present invention simulates the conditions and characteristics of a human nail, especially the hydrophilic membranes of the nail.
• Polyethylene glycols and poloxamers have an occlusive effect which enhances the level of hydration of the nail.
• the PEG or poloxamer / PEG-ether mixture of the formulation of the present invention is skin compatible and breathable.
• the formulation has a pH of about 5.5, which simulates the conditions of human skin.
• formulations of the present invention are two-way transport of the pharmaceutically active agent into and across the hydrophilic nail: transungual and transdermal.
• the onychomycosis will be treated by an application of the formulations of the present invention not only on the nail, but also on the surrounding skin area.
• Another advantage of the formulation of the present invention is that compared to other hydrophilic gels (e.g. on the basis of hydroxymethyl cellulose or PEG), the PEG or poloxamer / PEG-ether mixture showed surprisingly excellent drying times that are comparable or even better than those of conventional lacquers (e.g. based on polyvinylacetate, (meth)acrylic acid alkyl ester copolymers, or methylvinyl ether maleic acid monoalkyl ester copolymers).
• lacquers e.g. based on polyvinylacetate, (meth)acrylic acid alkyl ester copolymers, or methylvinyl ether maleic acid monoalkyl ester copolymers.
• the formulation of the present invention can be washed off. This results in better patient compliance, because it avoids the need for time consuming removal of conventional nail lacquers by filing or the use of solvent based formulations.
• Standard nail lacquers have to be removed at least weekly with alcoholic wipes and by using a nail file. Especially for older patients, this therapy plan is difficult to adopt.
• the use of a nail file can induce severe injuries of the skin surrounding the nail, which can result in systemic uptake of fungi.
• the formulations of the present invention will ease the therapy plan for patients, because the formulations can be removed easily by washing. Therefore the formulations of the present invention increase patient compliance.
• Example 2 proximal flux and affinity of three abafungin formulations into horse hoof horn membranes
• Example 3 ex vivo penetration studies of three abafungin formulations into horse hoof horn membranes
• Animal hoof is made of essentially the same material as human nails. Horse hoof was sawn into horn membranes having an area of about 2cm 2 and a thickness of 600-700 ⁇ m which conforms to human nails. Human finger nails are about 500 ⁇ m thick and human toenails about 800 ⁇ m.
• ImI of each of formulations 1, 2 and 3 of example 2 was applied to a horse hoof horn membrane.
• the horse hoof horn membranes were placed in Franz diffusion cells (area 1.76cm 2 ) and the cells were filled with a tempered blood simulating buffer (phosphate buffered saline). The buffer was stirred at 300rpm. After 24 hours, the horse hoof horn membranes were removed from the Franz diffusion cells and residues of the formulations were removed.
• the effective penetration area of 1.76cm 2 was cut into small pieces and abafungin was extracted using a mixture of 80% acetonitrile, 19.6% water and 0.4% perchloric acid. The samples were extracted for 30 minutes using an ultrasonic water bath at 60 0 C. The supernatant was analysed using HPLC.
• Example 4 penetration of abafungin into stratum corneum and epidermis/dermis
• a hydrophilic gel formulation according to the present invention was prepared, comprising the ingredients set out in Table 4.
• the formulation was the same as formulation 2 in example 2.
• the gel formulation was prepared by dissolving abafungin and formic acid in water. Then the remaining ingredients (namely 2-propanol, PEG 20000, PEG 8000, MPEG 2000, isopropyl myristate, transcutol, and propylene glycol) were added to this solution and the mixture was stirred until a gel formulation was formed.
• the remaining ingredients namely 2-propanol, PEG 20000, PEG 8000, MPEG 2000, isopropyl myristate, transcutol, and propylene glycol
• the gel formulation was applied once daily to the left toenail of a male volunteer (aged 32) suffering from onychomycosis.
• the results are shown in Figure 3, which shows the toenail (a) after one month, (b) after two months, and (c) after three months of once daily application of the formulation. There is a marked improvement in the toenail's condition.
• a second male volunteer (aged 55), also suffering from onychomycosis, was treated orally with 100 mg itraconazole (Itracol ® ) twice daily for one week followed by three weeks intermission. After one month of itraconazole administration, the volunteer additionally applied the gel formulation once daily to his toenails.
• Figure 4 shows the toenails (a) before treatment, (b) after one month of itraconazole administration, (c) after two months of itraconazole administration and one month application of the abafungin formulation, (d) after three months of itraconazole administration and two months application of the abafungin formulation, and (e) after four months of itraconazole administration and three months application of the abafungin formulation. There is a marked improvement in the toenails' condition.
• Example 6 ex vivo penetration studies of five formulations comprising abafungin, ciclopirox or ciclopirox olamine into horse hoof horn membranes
• Animal hoof is made of essentially the same material as human nails. Horse hoof was sawn into horn membranes having an area of about 2cm 2 and a thickness of 600-700 ⁇ m which conforms to human nails. Human finger nails are about 500 ⁇ m thick and human toenails about 800 ⁇ m.
• Formulations 1-3 and 5 were prepared and formulation 4 was purchased, comprising the ingredients set out in Table 5.
• Formulations 1, 2 and 5 were hydrophilic gels, and formulations 3 and 4 were lacquers.
• Formulations 2 and 5 are according to the present invention, and formulations 1, 3 and 4 are comparative formulations.
• Table 5 commercially available Batrafen ® (also called Penlac ® ), therefore amounts of excipients unknown 250 ⁇ l of each of formulations 1-5 was applied to a horse hoof horn membrane.
• the horse hoof horn membranes were placed in Franz diffusion cells (area 1.76cm 2 ) and the cells were filled with a tempered blood simulating buffer (phosphate buffered saline). The buffer was stirred at 300rpm. After 24 hours, the horse hoof horn membranes were removed from the Franz diffusion cells and the residues of the formulations were removed. The effective penetration area of 1.76cm 2 was cut into small pieces and the API (abafungin, ciclopirox, or ciclopirox olamine) was extracted using an appropriate solvent. The samples were extracted for 30 minutes using an ultrasonic bath at 60 0 C. The supernatant was analysed using HPLC.
• API abafungin, ciclopirox, or ciclopirox olamine
• Porcine ear skin is made of essentially the same material as human skin. Porcine ear skin was removed carefully from the chondral tissue and cut into pieces having an area of about 2cm 2 and a thickness of about 2000 ⁇ m which conforms to human skin.
• Formulations a, b and d were prepared and formulation c was purchased, comprising the ingredients set out in Table 7.
• Formulations a and d were hydrophilic gels according to the present invention, and formulations b and c were comparative cream formulations.
• hydrocortisone formulation according to the present invention enhances the penetration rate of the corticosteroid hydrocortisone in comparison to the marketed formulation Hydrodexan Creme (formulation c).
• formulation d enhances the penetration rate of the corticosteroid hydrocortisone in comparison to the marketed formulation Hydrodexan Creme (formulation c).
• Example 8 solubility and stability studies with abafungin, hydrocortisone and ciclopirox olamine
• thumbnails of three volunteers were treated with three different formulations, namely a formulation according to the present invention (formulation 2 of example 2) and commercially available lacquer formulations Batrafen and Loceryl .
• the TEWL of the thumbnail was measured before and one hour after treatment of the three volunteers.
• the results are presented in Figure 7, which shows the percentage deviation of the measurements one hour after treatment to the measurements before the treatment.
• Both, the Batrafen and Loceryl lacquers resulted in a significant reduction of water loss and humidity above the nail. Only with the formulation according to the present invention, the free nail water can still permeate freely across the nail plate, moisten the nail plate and dissolve the pharmaceutically active agent out of the hydrophilic gel formulation into the nail.
• the objective of this study was to determine the ability of abafungin, formulated according to the present invention, to permeate through bovine hoof horn membrane (a model of human nail) and inhibit the growth of Trichophyton rubrum 34.
• T. rubrum is the most prevalent pathogen responsible for onychomycosis of the toenail (W.K. Foster, M.A. Ghannoum and B. E. Elewski, J. Am. Acad. Dermatol., 2004, vol. 50, pages 748-752).
• A was tested alongside three alternative abafungin formulations not according to the present invention (B-D) for comparative purposes.
• Bovine hoof horn membranes were hydrated in sterile distilled water in petri dishes for 2 hours. Subsequently, the bovine hoof horn membranes were removed from the petri dishes and dried on a filter paper.
• Drug formulations A-D were applied onto the bovine hoof horn membranes.
• a blank, untreated bovine hoof horn membrane was used as a control. Once the treatments had dried, the bovine hoof horn membranes were placed with the treated surface uppermost in the middle of an inoculated Sabouraud plate and the plates were incubated at 27°C for 5 days. Three repetitions of each test condition were performed.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Dermatology (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Zoology (AREA)
• Virology (AREA)
• Gynecology & Obstetrics (AREA)
• Endocrinology (AREA)
• Reproductive Health (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (3)

Applications Claiming Priority (2)

Publications (2)

Family

ID=38829743

Family Applications (1)

Country Status (5)

Cited By (12)

Families Citing this family (5)

Family Cites Families (24)

• 2007
  • 2007-10-23 GB GBGB0720716.0A patent/GB0720716D0/en not_active Ceased
• 2008
  • 2008-10-22 JP JP2010530562A patent/JP2011500779A/ja active Pending
  • 2008-10-22 WO PCT/GB2008/050978 patent/WO2009053741A2/en not_active Ceased
  • 2008-10-22 US US12/739,518 patent/US20110059985A1/en not_active Abandoned
  • 2008-10-22 EP EP08842974A patent/EP2331086A2/en not_active Ceased

Also Published As

Similar Documents

Legal Events